New psoriasis drug could be cheaper alternative to tremfya

NCT ID NCT07511647

Recruiting now Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial is testing whether a new drug called QL2106 works as well as the approved medication Tremfya for people with moderate to severe plaque psoriasis. About 318 participants will receive either QL2106 or Tremfya injections over several months. The main goal is to see if QL2106 can achieve at least a 75% improvement in psoriasis symptoms by week 16.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QL2106 injection (a proposed biosimilar to guselkumab, the active ingredient in Tremfya)
What this could lead to: If QL2106 works as well as Tremfya, it could offer a more affordable treatment option for people with moderate to severe plaque psoriasis.
What could go wrong: This is a biosimilar trial, so it's not testing a new drug mechanism. Success depends on proving QL2106 is not inferior to Tremfya, and long-term safety data are still limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Jining No.1 People's Hospital
RECRUITING

Jining, Shandong, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.